 | | |
|
|
|
|
|
|
News
Release: May 4, 2006
James Shapiro, M.D. Joins Sanguine in Developing Islet Cell Transportation Testing
PASADENA, Calif.--(HSMN NewsFeed)--May 4, 2006--Sanguine Corp. (OTCBB: SGNC ), a biopharmaceutical company focused on the development of an oxygen-carrying synthetic substitute for human red blood cells and numerous other areas requiring oxygen profusion, has selected, in conjunction with its FDA testing contractor, James Shapiro of the University of Alberta at Edmonton to develop and complete Sanguine's FDA testing program. With Dr. Shapiro's assistance, the compilation of data, including completed animal trials, PHER-O2 chemical data and other Sanguine proprietary information, is expected to be complete in the next two weeks. The data will be presented to the FDA as part of a pre-IND (Investigational New Drug) application. The company expects to complete this phase within the next 60 days.
Shapiro is the director of the clinical islet transplant program at the University of Alberta in Edmonton, Canada, and holds a clinical research professorial chair in transplantation research. He is a transplant surgeon who conducted extensive research in islet transplantation in the laboratory that formed the background to the current success of the Edmonton Group in numerous patients who have remained off insulin for longer than one year. He is the lead author of a paper in The New England Journal of Medicine showing successful transplantation of seven Type 1 diabetics at the University of Alberta. He received an M.D. from the University of Newcastle and trained in surgery in England.
As the director of the clinical islet transplant program, Shapiro led the clinical team, and together with Dr. Lakey and others, developed and tested a new protocol that used a steroid-free antirejection regimen, together with sufficient numbers of transplanted islets. Using this protocol, clinical success was improved from 8% to 100% insulin independence at one year. http://www.isletmedical.com/pdf/NEJM_Shapiro_Edmonton_Protocol.pdf
Dr. Thomas C. Drees, Ph.D., president and CEO of Sanguine Corp., added, "Drs. Shapiro and Lakey have been instrumental in developing real, long-term cures for patients who suffer from juvenile diabetes. By adding Dr. Shapiro to our medical team, we are well suited to successfully complete our pre-IND FDA meeting in the near future. We look forward to using PHER-O2 as a transport medium to aid in all transport tissue, including everything from islet cells to kidneys, livers and hearts."
For information related to the Sanguine Corp., contact Investor Relations: Michael Dancy, 801-746-3570, e-mail: medancy@allwest.net, or visit: www.sanguine-corp.com.
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the company's products, increased levels of competition for the company, new products and technological changes, the company's dependence on third-party suppliers, and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.
|
Source: Sanguine
Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.
|
 |
|
|
Public
Feeds 
